Is Myrtol® Standardized a New Alternative toward Antibiotics?
Standard
Is Myrtol® Standardized a New Alternative toward Antibiotics? / Paparoupa, Maria; Gillissen, Adrian.
in: Pharmacogn Rev, Jahrgang 10, Nr. 20, 14.01.2017, S. 143-146.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Is Myrtol® Standardized a New Alternative toward Antibiotics?
AU - Paparoupa, Maria
AU - Gillissen, Adrian
PY - 2017/1/14
Y1 - 2017/1/14
N2 - GeloMyrtol(®) and GeloMyrtol(®) forte, also known as Myrtol(®) standardized, is an herbal medical product (phytomedicine) obtained by a multistep distillation procedure from essential oils. The major biological marker of in vivo and ex vivo activity of Myrtol(®) standardized is the monoterpenes, d-limonene, 1,8-cineole, and alpha-pinene. Myrtol(®) standardized is estimated to have antioxidative, anti-inflammatory, and antibacterial potential while many studies confirmed its secretolytic and bronchospasmolytic effects. As such, the medication is proposed to be initiated in several acute and chronic infections of the upper and lower airway system as acute and chronic rhinosinusitis, acute and chronic bronchitis, and chronic obstructive pulmonary disease. This review intends to give an insight into several prescription indications of Myrtol(®) standardized, all involved mechanisms, and potential advantages toward antibiotic therapy, especially in cases when bacterial infection is uncertain.
AB - GeloMyrtol(®) and GeloMyrtol(®) forte, also known as Myrtol(®) standardized, is an herbal medical product (phytomedicine) obtained by a multistep distillation procedure from essential oils. The major biological marker of in vivo and ex vivo activity of Myrtol(®) standardized is the monoterpenes, d-limonene, 1,8-cineole, and alpha-pinene. Myrtol(®) standardized is estimated to have antioxidative, anti-inflammatory, and antibacterial potential while many studies confirmed its secretolytic and bronchospasmolytic effects. As such, the medication is proposed to be initiated in several acute and chronic infections of the upper and lower airway system as acute and chronic rhinosinusitis, acute and chronic bronchitis, and chronic obstructive pulmonary disease. This review intends to give an insight into several prescription indications of Myrtol(®) standardized, all involved mechanisms, and potential advantages toward antibiotic therapy, especially in cases when bacterial infection is uncertain.
KW - Review
KW - Journal Article
U2 - 10.4103/0973-7847.194045
DO - 10.4103/0973-7847.194045
M3 - SCORING: Review article
C2 - 28082798
VL - 10
SP - 143
EP - 146
JO - Pharmacogn Rev
JF - Pharmacogn Rev
SN - 0973-7847
IS - 20
ER -